DANVERS, Mass.
& SAN FRANCISCO–(BUSINESS WIRE)–Abiomed Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced
new results from a multicenter retrospective study demonstrating that early
initiation of support with Impella® 2.5 prior to revascularization improves
survival in emergent patients as compared to those receiving Impella 2.5
support after percutaneous coronary intervention (PCI). Specifically, the
analysis demonstrated that shock patients that received Impella before
revascularization had a higher survival rate (65% vs. 39%, p=0.007
respectively, N=119).
The results of the study were presented today by William
ONeill, M.D. of the University of Miami, at the annual 2011 Transcatheter
Cardiovascular Therapeutics (TCT) meeting and included 119 patients receiving
emergent PCI with Impella at 32 U.S.
centers.
The data from this analysis supports the recently released
new ACCF/AHA/SCAI guidelines which included Impella as a Class I recommendation
for cardiogenic shock after STEMI.
5.2.3 Cardiogenic Shock Class I: Recommendation: “A
hemodynamic support device is recommended for patients with cardiogenic shock
after STEMI who do not quickly stabilize with pharmacological therapy (384,424–427).
(Level of Evidence: B).”
This is an ongoing registry that continues to analyze this
data and collect data for the Impella patient population. The slides from this
presentation will be made available on www.TCTMD.com on Friday, November 11, 2011.
ABOUT ABIOMED
Based in Danvers, Massachusetts, Abiomed, Inc. is a leading
provider of medical devices that provide circulatory support to acute heart
failure patients across the continuum of care in heart recovery. Our products
are designed to enable the heart to rest, heal and recover by improving blood
flow and/or performing the pumping of the heart. For additional information
please visit: www.abiomed.com.
